BioXcel's BXCL101, Receives Orphan Drug Designation from the U.S. FDA for the Treatment of Patients with Neurofibromatosis Type 2 (NF2) - EconoTimes

Open in new window

The document is on a web server that cannot be reached. Please try again later.